GlassScriptPhysician profile
Keilah B Ford
NPI 1871980730
$3,892.17
in general payments reported to CMS, 2019-2025
24 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $1,514 · 2023: $680 · 2024: $293 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.72 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $509.82 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Lundbeck LLC | $291.29 | 2021-2023 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $273.20 | 2021-2022 | |
| Alkermes, INC. | $227.66 | 2021-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.88 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $200.69 | 2021-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $191.06 | 2021-2024 | Austedo Xr, Austedo |
| Ars Pharmaceuticals Operations, INC. | $188.88 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $166.78 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $146.59 | 2021-2025 | Trintellix |
| Viiv Healthcare Company | $118.63 | 2025 | |
| Novo Nordisk INC | $106.53 | 2022 | |
| Corium, LLC | $105.68 | 2022-2023 | Azstarys |
| Lilly USA, LLC | $99.37 | 2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $73.76 | 2022 | |
| Vanda Pharmaceuticals INC. | $70.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $54.48 | 2021-2022 | |
| Indivior INC. | $44.09 | 2022 | |
| Eisai INC. | $25.00 | 2021 | |
| Noven Therapeutics, LLC | $24.41 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.63 | 2021 | |
| Avanir Pharmaceuticals, INC. | $21.03 | 2021 | |
| Almatica Pharma LLC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keilah Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.